A carregar...
First-line alectinib for ALK-positive lung cancer: is there room for further improvement?
In the present editorial we describe the therapeutic achievements in the treatment of patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). We focus on the major breakthroughs we have been witnessing in this context, from the introduction of crizotinib...
Na minha lista:
| Publicado no: | Drugs Context |
|---|---|
| Main Authors: | , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
BioExcel Publishing Ltd
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6044318/ https://ncbi.nlm.nih.gov/pubmed/30023004 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212537 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|